These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 10500344)

  • 1. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
    Chew DP; Moliterno DJ
    Cleve Clin J Med; 2001 Dec; 68(12):1017-23. PubMed ID: 11765119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
    King S; Short M; Harmon C
    Vascul Pharmacol; 2016 Mar; 78():10-6. PubMed ID: 26187354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?
    Musumeci G; Baroni M; Rossini R
    Curr Vasc Pharmacol; 2012 Jul; 10(4):443-7. PubMed ID: 22339252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
    Kleiman NS
    Coron Artery Dis; 1998; 9(9):603-16. PubMed ID: 9861523
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
    Neumann FJ; Hochholzer W; Pogatsa-Murray G; Schömig A; Gawaz M
    J Am Coll Cardiol; 2001 Apr; 37(5):1323-8. PubMed ID: 11300442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.
    Memon MA; Blankenship JC; Wood GC; Frey CM; Menapace FJ
    Am J Med; 2000 Aug; 109(3):213-7. PubMed ID: 10974184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Lazar J; Cavusoglu E
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):214-21. PubMed ID: 19156882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 16. Current issues with glycoprotein IIb-IIIa antagonists.
    Schneider DJ
    Curr Drug Targets; 2011 Nov; 12(12):1813-20. PubMed ID: 21718238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.
    Störk T; Fröhlich E; Möckel M
    Lancet; 2001 Dec; 358(9297):1996-7. PubMed ID: 11747950
    [No Abstract]   [Full Text] [Related]  

  • 18. A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.
    Vakili BA; Kaplan RC; Slater JN; Sherman W; Ravi KL; Green SJ; Sanborn TA; Brown DL
    Am J Cardiol; 2003 Apr; 91(8):946-50. PubMed ID: 12686333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
    Gowda RM; Khan IA; Vasavada BC; Sacchi TJ
    Am J Ther; 2004; 11(4):302-7. PubMed ID: 15266223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Gibson CM; Moynihan JL; Al-Mousa EN; Campsey M; Gandhi R; Murphy S; Mattson S; Ryan KA; Mesley R; Swanson J; Arshad MN; Marble SJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):287-302. PubMed ID: 10375390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.